The global fabry disease treatment market size is estimated to reach a value of USD 3.12 billion by 2025, according to a new report by Grand View Research, Inc., exhibiting a CAGR of 9.6% during the forecast period. Rising cohort of Fabry disease, increasing adoption of novel therapies such as chaperone treatment, and potential approval of pipeline drugs including substrate reduction therapies and enzyme replacement therapies are providing a fillip to the market.
Fabry
disease is a rare inherited lysosomal storage disorder caused by genetic
mutation that interferes with function of alpha galactosidase enzyme. Fabry
disease generally has a late onset with mild symptoms, due to which several
patients are often undiagnosed. Standard of care for management of the disease
is enzyme replacement therapy (ERT). Sanofi’s Fabrazyme and Shire’s Replagal
are the only approved ERTs in the EU; however in the U.S., only Fabrazyme has
been approved.
Focus
of current clinical trials is to improve the safety and efficacy profile of
ERTs and introduction of novel oral therapies that can eliminate the need for
intravenous infusions. Recently, Amicus Therapeutics’ Galafold has been
approved as the first oral chaperone therapy for the treatment of adults in the
U.S., Canada, EU, Japan, Australia, Israel, and South Korea.
North
America held the largest share in the Fabry disease treatment market in 2017,
followed by Europe. The growth of the region can be attributed to higher
adoption of novel therapies, favorable reimbursement policies, and better
healthcare facilities. However, high cost of therapy with ERTs such as
Fabrazyme is an impediment for the market in developing regions.
For more info visit here: https://www.grandviewresearch.com/industry-analysis/fabry-disease-treatment-market
Further Key
Findings From the Study Suggest:
- Although the
exact prevalence is unknown, Fabry disease affects approximately one in
40,000 males
- The enzyme
replacement therapy segment led the market with over 85.0% market share in
2017 due to strong sales of Fabrazyme and Replagal.
- North America
commanded the leading market share of more than 45.0% in the Fabry disease
treatment market, followed by Europe, in 2017
- APAC is
likely to witness the fastest growth during the forecast period, followed
by Latin America, due to increasing healthcare expenditure and rising
patient population
- Some of the
key players in the market are Sanofi S.A.; Shire Plc.; Amicus Therapeutics
Inc.; ISU Abxis Co Ltd.; JCR Pharmaceuticals Co Ltd.; Protalix
Biotherapeutics Inc.; Idorsia Pharmaceuticals Ltd.; Avrobio Inc.;
Greenovation Biotech GmbH; Moderna Therapeutics Inc.; and Green Cross
Pharma Pte Ltd.
Grand View Research has
segmented the global fabry disease treatment market on the basis of treatment
and region:
Fabry Disease
Treatment Outlook (Revenue, USD Million, 2016 - 2025)
- Enzyme Replacement Therapy (ERT)
- Chaperone Treatment
- Substrate Reduction Therapy (SRT)
- Others
Fabry Disease
Treatment Region Outlook (Revenue, USD Million, 2016 - 2025)
- North America
- U.S.
- Canada
- Europe
- Germany
- U.K.
- Asia Pacific
- Japan
- China
- India
- Latin America
- Brazil
- Mexico
- MEA
- South Africa
Request a Sample Copy @ https://www.grandviewresearch.com/industry-analysis/fabry-disease-treatment-market/request/rs1
About Grand View Research
Grand
View Research, Inc. is a U.S. based market research and consulting company,
registered in the State of California and headquartered in San Francisco. The
company provides syndicated research reports, customized research reports, and
consulting services. To help clients make informed business decisions, we offer
market intelligence studies ensuring relevant and fact-based research across a
range of industries, from technology to chemicals, materials and healthcare.
For more info visit @ https://www.grandviewresearch.com
No comments:
Post a Comment